M&A Deal Summary |
|
|---|---|
| Date | 2021-04-27 |
| Target | Acti-Med |
| Sector | Medical Products |
| Buyer(s) |
Gilde Healthcare
Kartesia |
| Deal Type | Buyout (LBO, MBO, MBI) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Private Equity Firm |
|---|---|
| Founded | 1999 |
| PE ASSETS | 2.6B EUR |
| Size | Large |
| Type | Sector Focused |
Gilde Healthcare is a specialist private equity and venture investor focused on the healthcare sector. The Firm's buyout group targets majority investments throughout Europe (preference for Germany, the Netherlands, Belgium, Austria or Switzerland) and has a focus on healthcare providers, suppliers and service providers active in the healthcare market. The Firm's venture group looks to invest in early stage medtech, diagnostics, digital health and therapeutics companies throughout North America and Europe. Gilde Healthcare was established in 2001 and is headquartered in Utrecht, the Netherlands.
| DEAL STATS | # |
|---|---|
| Overall | 40 of 47 |
| Sector (Medical Products) | 9 of 12 |
| Type (Buyout (LBO, MBO, MBI)) | 3 of 8 |
| Country (Germany) | 4 of 6 |
| Year (2021) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-06-04 |
Symphogen AS
Ballerup, Denmark Symphogen AS is a polyclonal antibody technology that provides a totally new, innovative class of biopharmaceuticals for treating serious human diseases. Symphogen was founded in 2000 and is based in Ballerup, Denmark. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-06 |
KLIFO
Glostrup, Denmark KLIFO is a drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. KLIFO provides end-to-end expert capabilities, enabling partners to maximize opportunity, mitigate risks, drive innovation and achieve efficient project advancement. KLIFO was founded in 1994 and is based in Glostrup, Denmark. |
Buy | - |
Kartesia is a private investment group and lender that looks to invest in lower middle-market companies throughout the European Union and Central Europe. The Firm is industry agnostic and seeks to commit €10 to €100 million in profitable companies with at least €5 million of EBITDA. Proceeds are typically invested alongside sponsors to support buyouts, recapitalizations, shareholder liquidity needs, or restructurings. Kartesia was established in 2013 and is headquartered in London.
| DEAL STATS | # |
|---|---|
| Overall | 17 of 30 |
| Sector (Medical Products) | 1 of 1 |
| Type (Buyout (LBO, MBO, MBI)) | 8 of 11 |
| Country (Germany) | 4 of 7 |
| Year (2021) | 2 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-03-04 |
Bioscript
Cheshire, United Kingdom Bioscript is an international provider of medical communications and regulatory writing services for pharmaceutical companies. The business assists clients in their communications with regulatory authorities as well as educating the medical sector on pharmaceutical products that are in mid-to-late-stage clinical trials and subsequently supporting these products, post-market launch, to maintain and grow sales throughout the lifecycle of the drug. Bioscript was founded in 2005 and is based in Cheshire, United Kingdom. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-04 |
EidosMedia
Milan, Italy EidosMedia is a Content Management System (CMS) solutions company that develops innovative content management solutions to serve clients with high-value content and complex workflow management needs. Its software covers the end-to-end content lifecycle for very large media, financial research, academic, and public research, and corporate organizations. EidosMedia was formed in 1999 and is based in Milan, Italy. |
Buy | - |
